Trials / Completed
CompletedNCT05306210
Forxiga CKD Japan Post-Marketing Surveillance (PMS)
Forxiga Tablets 5mg, 10mgGeneral Drug Use-Results Study n in Chronic Kidney Disease (CKD) Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,029 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To capture safety when Forxige is administrated to CKD patients in the real world setting
Detailed description
The purpose of the study is to review the following points during use of Forxiga Tablets (hereinafter referred to as Forxiga) in the real world setting after launch for treatment of CKD. 1. ADRs which are unexpected from the precautions for use in our JPI 2. Understanding of incidence of ADRs during use of Forxiga in the real world setting 3. Factors (ie demography, treatment) possibly having an impact on the safety.
Conditions
Timeline
- Start date
- 2022-04-12
- Primary completion
- 2024-10-08
- Completion
- 2024-10-08
- First posted
- 2022-04-01
- Last updated
- 2025-10-09
Locations
46 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT05306210. Inclusion in this directory is not an endorsement.